Complete remission of relapsed mixed cellularity Hodgkin's disease treated with rituximab;Komplette remission eines rezidivierenden Hodgkin-lymphoms vom mischzelligen typ nach rituximab-therapie

Deutsche Medizinische Wochenschrift

Volumn 132, Issue 33, 2007, Pages 1688-1691

  Al Ali, Haifa Kathrin ^a   Wittekind, C ^a   Niederwieser, D ^a  

^a UNIVERSITY HOSPITAL LEIPZIG   (Germany)

Author keywords

B cells; CD20 antigen; Lymphoma; Monoclonal antibody

Indexed keywords

BLEOMYCIN; CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DEXAMETHASONE; DOXORUBICIN; ETOPOFOS; GEMCITABINE; MELPHALAN; PREDNISONE; PROCARBAZINE; RITUXIMAB; VINBLASTINE; VINCRISTINE; ABVD PROTOCOL; ANTINEOPLASTIC AGENT; COPP PROTOCOL; DEXA BEAM PROTOCOL; DEXA-BEAM PROTOCOL; ETOPOSIDE; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER STAGING; CASE REPORT; CERVICAL LYMPHADENOPATHY; COMBINATION CHEMOTHERAPY; DISEASE CLASSIFICATION; DISEASE COURSE; HUMAN; HUMAN TISSUE; MALE; MIXED CELLULARITY HODGKIN LYMPHOMA; RECURRENT DISEASE; REED STERNBERG CELL; REMISSION; STEM CELL TRANSPLANTATION; TREATMENT RESPONSE; HODGKIN DISEASE; LYMPH NODE; METHODOLOGY; MIDDLE AGED; PATHOLOGY; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; TREATMENT OUTCOME; TUMOR RECURRENCE;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; HODGKIN DISEASE; HUMANS; LYMPH NODES; MALE; MELPHALAN; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PREDNISONE; PROCARBAZINE; REMISSION INDUCTION; TREATMENT OUTCOME; VINBLASTINE; VINCRISTINE;

EID: 34548165108     PISSN: 00120472     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-984950     Document Type: Article

References (15)

1. Bradley C, Ekstrand , Jennifer B et al. Rituximab in lymphocyte-predominant Hodgkin disease: results of a phase 2 trial. Blood 2003; 101: 4285-4289
2. Coiffier B, Haioun C, Ketterer N et al. Rituximab (Anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: A multicenter phase II study. Blood 1998; 2: 1927-1932
3. Henry-Amar M. Second cancer after treatment of Hodgkin's disease: a report from the International Database on Hodgkin's Disease. Ann Oncol 1992; 3: 117-128
4. Küppers R, Rajewsky K. The origin of Hodgkin and Reed/Sternberg cells in Hodgkin's disease. Annu Rev Immunol 1998; 16: 471-493
5. Marafioti T, Hummel M, Anagnostopoulos I et al. Origin of nodular lymphocyte-predominant Hodgkin's disease from a clonal expansion of highly mutated germinal-center B-cells. N Engl J Med 1997; 337: 453-458
6. Mason DY, Banks PM, Chan J et al. Nodular lymphocyte predominance Hodgkin's disease. A clinicopathological entity. Am J Surg Pathol 1994; 18: 526-530
7. Mclaughlin P, Grillo-Lopez AJ, Link PK et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to four-dose treatment program. J Clin Oncol 1998; 16: 2825-2833
8. Miettinen M, Franssila KO, Saxen E. Hodgkin's disease, lymphocyte predominance nodular: increased risk of subsequent non-Hodgkin's lymphoma. Cancer 1983; 51: 2293-2300
9. Ohno T, Stribley JA, Wu G, Hinrichs SH, Weisenburger DD. Chan WC. Clonality in nodular lymphocyte-predominant Hodgkin's disease. N Engl J Med 1997; 337: 459-465
10. Rehwald U, Schulz H, Reiser M et al. Treatment of relapsed CD20+ Hodgkin lymphoma with the monoclonal antibody rituximab is effective and well tolerated: results of a phase 2 trial of the German Hodgkin Lymphoma Study Group. Blood 2003; 101: 420-424
11. Schmid C, Pan L, Diss T, Isaacson PG. Expression of B-cell antigens b Hodgkin's and Reed-Sternberg cells. Am J Pathol 1991; 139: 701-707
12. Wasielewski R von, Mengel M, Fischer R et al. Classical Hodgkin's disease. Clinical impact of the immunophenotype. Am J Pathol 1997; 151: 1123-1130
13. Watanabe K, Yamashita Y, Nakayama A et al. Varied B-cell immunophenotypes of Hodgkin/Reed-Sternberg cells in classic Hodgkin's disease. Histopathology 2000; 36: 353-361
14. Younes A, Romaguera J, Hagemeister F et al. A pilot study of rituximab in patients with recurrent, classic Hodgkin disease. Cancer 2003(298: 310-314
15. Zuckerberg LR, Collins AB, Ferry JA, Harris NL. Coexpression of CD15 and CD20 by Reed-Sternberg cells in Hodgkin's disease. Am J Pathol 1991; 139: 475-483